Anebulo Pharmaceuticals, Inc. (ANEB)
OTCMKTS · Delayed Price · Currency is USD
0.3975
-0.0225 (-5.36%)
At close: Aug 18, 2026

Anebulo Pharmaceuticals Financials Overview

Millions USD. Fiscal year is Jul - Jun.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21
Operating Income
-9.1-9.22-8.31-11.78-6.83-3.61
Net Income
-7.98-8.48-8.2-11.73-6.83-38.46
Earnings Per Share
-0.19-0.25-0.32-0.47-0.29-2.83
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21
Cash & Investments
9.0411.633.0911.2514.5519.99
Total Debt
------
Net Cash (Debt)
9.0411.633.0911.2514.5519.99
Net Cash Growth
-39.72%275.80%-72.49%-22.69%-27.21%607.78%
Net Cash Per Share
0.220.340.120.450.621.47

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21
Operating Cash Flow
-5.84-6.35-8.09-9.68-5.44-4.87
Free Cash Flow
-5.84-6.35-8.09-9.68-5.44-4.87
Free Cash Flow Growth
------

Valuation

Selected indicators aren't available for this stock.